Baidu
map

EASL 2014 :CT测定腰大肌厚度可判断肝硬化患者预后

2014-04-14 佚名 dxy

长期以来,对于终末期肝病都没有一个较完善的评分指标以评价其严重程度。终末期肝病模型(Model for end-stage liver disease,MELD)标准可对终末期肝病短中期死亡率进行有效的预测,并因其评价指标易得、客观、易于计算,在肝病诊治中广为应用。 然而,MELD分级中使用的血清肌酐、胆红素、INR等指标,容易受非肝病因素的影响,这将直接影响判断真实的肝病病情。对于MELD评分较

长期以来,对于终末期肝病都没有一个较完善的评分指标以评价其严重程度。终末期肝病模型(Model for end-stage liver disease,MELD)标准可对终末期肝病短中期死亡率进行有效的预测,并因其评价指标易得、客观、易于计算,在肝病诊治中广为应用。

然而,MELD分级中使用的血清肌酐、胆红素、INR等指标,容易受非肝病因素的影响,这将直接影响判断真实的肝病病情。对于MELD评分较低且有顽固性腹水的病人,预后死亡率的判断相对更加困难。本研究即旨在探究利用肌肉萎缩程度指标是否可提高MELD评分预测的精准性。

研究对前期终末期肝病队列研究的186名患者和正处于终末期肝病队列研究的376名患者进行了评价。CT测量脐水平线腰横肌厚度,前期终末期肝病研究患者的 TPMT/height (腰横肌厚度) 和终末期肝病评分被用以估算患者的死亡率,所得结果在处于终末期肝病研究的患者中进行验证。
研究结果发现,在前期终末期肝病患者的队列研究中, MELD 评分和腰横肌肉厚度与死亡率有密切关系,MELD和 TPMT/height的综合评分误差为0.84。

在对正处于终末期肝病患者的队列研究中,独立于MELD和MELD-Na评分系统的TPMT/height(腰横肌厚度)也与患者死亡率有显著相关性。腰横肌厚度每减少一个单位量,死亡风险就会增加15% ,TPMT/height评分误差值为0.82,优于 MELD评分和 MELD-Na评分。TPMT/height小于16.8mm时,难治性腹水病人的死亡率明显升高。

研究表明,脐水平的腰横肌厚度可以作为肌肉萎缩的客观标志, 进而可以作为预测肝硬化病人死亡率的一个客观标志, 这种测量方法独立于 MELD 和MELD-Na 评分之外,也可以帮助临床医生更好地评价难治性腹水患者的预后。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1662213, encodeId=3ae71662213e7, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 17 10:30:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691827, encodeId=af38169182ef5, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 22 10:30:00 CST 2015, time=2015-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412501, encodeId=53c0141250158, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519163, encodeId=973d151916381, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1662213, encodeId=3ae71662213e7, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 17 10:30:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691827, encodeId=af38169182ef5, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 22 10:30:00 CST 2015, time=2015-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412501, encodeId=53c0141250158, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519163, encodeId=973d151916381, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1662213, encodeId=3ae71662213e7, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 17 10:30:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691827, encodeId=af38169182ef5, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 22 10:30:00 CST 2015, time=2015-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412501, encodeId=53c0141250158, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519163, encodeId=973d151916381, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-04-16 kord1983
  4. [GetPortalCommentsPageByObjectIdResponse(id=1662213, encodeId=3ae71662213e7, content=<a href='/topic/show?id=6a426545472' target=_blank style='color:#2F92EE;'>#测定#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65454, encryptionId=6a426545472, topicName=测定)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Thu Jul 17 10:30:00 CST 2014, time=2014-07-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1691827, encodeId=af38169182ef5, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Mar 22 10:30:00 CST 2015, time=2015-03-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412501, encodeId=53c0141250158, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519163, encodeId=973d151916381, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:30:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-04-16 lq1771

相关资讯

JID:1b期研究发现ITX5061治疗HCV效果有限

慢性HCV感染可引起肝硬化和肝细胞癌,是肝相关疾病发病和死亡的主要原因。现有的HCV治疗并不尽如人意,存在毒性、效果局限和顺应性差等缺点。尽管在细节方面仍存在诸多不清之处,但是HCV进入细胞所需要的细胞受体包括清道夫受体B类1型(SR-B1)、CD81、紧密连接蛋白1和闭锁蛋白。存在于多种细胞(包括肝细胞)膜上的整合跨膜蛋白ITX5061是一个高效的小分子SR-B1抑制剂。因为抑制SR-B1与血浆

EASL 2014 :TIPS10mm支架控制门脉高压更效果更优

一个单中心、小样本的随机临床试验(RCT)曾显示,对于肝硬化难治性腹水的患者,使用直径为8mm的支架(聚四氟乙烯膨体覆盖)行TIPS手术并不能有效控制门脉高压,且容易引起并发症。为了进一步从临床应用方面证实此项研究,来自意大利巴勒莫的Luca等进行了一项回顾性研究,其结果公布于2014年4月9日-4月13日在伦敦举行的EASL2014会上。 研究选择了连续的171例采用直径8mm或直径10mm支架

微创外科周 :肝硬化患者可行腹腔镜胆囊切除术

意大利福贾市大学的Vincenzo Neri医生在年度微创外科周上报告称,对于很多需要行胆囊切除操作的肝硬化患者而言,腹腔镜胆囊切除术是一种很好的选择。除了能快速有效地缓解急性疾病之外,腹腔镜胆囊切除术还可能提供未来获益。 他展示的这项回顾性分析的目的是在接受胆囊切除术的肝硬化患者中评估腹腔镜方法的安全性和有效性。这个系列中包括65例肝硬化和有症状的胆石症患者。其中,6例计划行开放式手术,其他行

MISS 2013:肝硬化患者接受腹腔镜胆囊切除术结局好

意大利福贾市大学的Vincenzo Neri医生在年度微创外科周上报告称,对于很多需要行胆囊切除操作的肝硬化患者而言,腹腔镜胆囊切除术是一种很好的选择。除了能快速有效地缓解急性疾病之外,腹腔镜胆囊切除术还可能提供未来获益。 他展示的这项回顾性分析的目的是在接受胆囊切除术的肝硬化患者中评估腹腔镜方法的安全性和有效性。这个系列中包括65例肝硬化和有症状的胆石症患者。其中,6例计划行开放式手术,其他行

EASL 2014:sofosbuvir+RBV对HCV肝硬化患者安全有效

HCV感染门静脉高压或肝硬化失代偿的患者,对于干扰素治疗的耐受性较差,低效,存在感染和死亡的风险。无干扰素治疗方案是一种理想的治疗。 哈佛大学Beth Israel Deaconess医学中心研究人员发现,sofosbuvir+利巴韦林治疗HCV肝硬化和门脉高压症(CPT 5-10)患者安全有效。该研究结果公布于2014年4月12日的EASL2014会议上。 患者随机接受48周的sofosbuvi

Baidu
map
Baidu
map
Baidu
map